Genoskin is a biotechnology company based in Toulouse (France) and Boston, MA (USA). The company is a leader and pioneer in standardized and ready-to-use human skin biopsies for ex vivo clinical testing. Thanks to a patented and unique technology platform, Genoskin accelerates the development of pharmaceutical, cosmetic and chemical products as well as biologics and medical devices, while minimizing the risks. Our cutting-edge technology enables the evaluation of topical and systemic administration, subcutaneous injection and anti-Th1/Th17 inflammatory drugs. We also provide tools for tissue culture as well as in-house R&D services. Our skin models offer a reliable alternative to animal testing and enables our clients to comply with regulatory and ethical requirements. The company is ISO9001:2015 certified.